Control of intraocular pressure fluctuation: are combination drugs more effective?

References

• Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol.126, 487–497 (1998).
   PubMed Web of Science ®Google Scholar
• The Advanced Glaucoma Intervention Study (AGIS) 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am. J. Ophthalmol.130, 429–440 (2000).
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression, results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol.120, 1268–1279 (2002).
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment Study, a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol.120, 701–713 (2002).
   PubMed Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology108, 1943–1953 (2001).
   PubMed Web of Science ®Google Scholar
• Nouri-Mahdavi K, Hoffman D, Coleman AL et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology111, 1627–1635 (2004).
   PubMed Web of Science ®Google Scholar
• Bengtsson B, Leske MC, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology114, 205–209 (2007).
   PubMed Web of Science ®Google Scholar
• Caprioli J. Intraocular pressure fluctuation, an independent risk factor for glaucoma? Arch. Ophthalmol.125, 1124–1125 (2007).
   PubMedGoogle Scholar
• Hong S, Seong GJ, Hong YJ. Long-term intraocular pressure fluctuation and progressive visual field deterioration in patients with glaucoma and low intraocular pressures after a triple procedure. Arch. Ophthalmol.125, 1010–1013 (2007).
   PubMed Web of Science ®Google Scholar
• Nakagami T, Yamazaki Y, Hayamizu F. Prognostic factors for progression of visual field damage in patients with normal-tension glaucoma. Jpn J. Ophthalmol.50, 38–43 (2006).
   PubMed Web of Science ®Google Scholar
• Sherwood MB, Craven ER, Chou C et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension, a 12-month randomized trial. Arch. Ophthalmol.124, 1230–1238 (2006).
   PubMed Web of Science ®Google Scholar
• Spaeth GL, Bernstein P, Caprioli J, Schiffman RM. Control of intraocular pressure and fluctuation with fixed-combination brimonidine–timolol versus brimonidine or timolol monotherapy. Am. J. Ophthalmol.151(1), 93–99.e4 (2011).
   PubMed Web of Science ®Google Scholar
• Sommer A, Tielsch JM, Katz J et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch. Ophthalmol.109, 1090–1095 (1991).
   PubMed Web of Science ®Google Scholar
• Boyle JE, Ghosh K, Gieser DK, Adamsons IA. A randomized trial comparing the dorzolamide–timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide–Timolol Study Group. Ophthalmology105, 1945–1951 (1998).
   PubMed Web of Science ®Google Scholar
• Bell NP, Ramos JL, Feldman RM. Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension. Clin. Ophthalmol.4, 1331–1346 (2010).
   PubMedGoogle Scholar
• Hong S, Kim CY, Seong GJ. Long-term intraocular pressure fluctuation and visual field progression in glaucoma patients with low intraocular pressure after post-trabeculectomy phacoemulsification. J. Ocul. Pharmacol. Ther.23, 571–576 (2007).
   PubMed Web of Science ®Google Scholar
• Day DG, Schacknow PN, Wand M et al. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol.135, 138–143 (2003).
   PubMed Web of Science ®Google Scholar
• Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily, 1-year results in glaucoma patients. Brimonidine Study Group. Am. J. Ophthalmol.127, 20–26 (1999).
   PubMed Web of Science ®Google Scholar
• Stewart WC, Stewart JA, Day D, Sharpe ED. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol. Scand.81, 242–246 (2003).
   PubMedGoogle Scholar
• Stewart WC, Stewart JA, Day DG, Sharpe ED, Jenkins JN. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy. Eye (Lond.)18, 990–995 (2004).
   PubMed Web of Science ®Google Scholar
• Konstas AG, Stewart WC, Topouzis F, Tersis I, Holmes KT, Stangos NT. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am. J. Ophthalmol.131, 729–733 (2001).
   PubMed Web of Science ®Google Scholar
• Liu JH, Medeiros FA, Slight JR, Weinreb RN. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology116, 449–454 (2009).
   PubMed Web of Science ®Google Scholar
• Liu JH, Medeiros FA, Slight JR, Weinreb RN. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology117, 2075–2079 (2010).
   PubMed Web of Science ®Google Scholar
• Liu JH, Zhang X, Kripke DF, Weinreb RN. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest. Ophthalmol. Vis. Sci.44, 1586–1590 (2003).
   PubMed Web of Science ®Google Scholar
• Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak nocturnal intraocular pressures in healthy subjects and glaucoma patients. Am. J. Ophthalmol.139(2), 320–324 (2005).
   PubMed Web of Science ®Google Scholar
• Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology115(7), 1117–1122.e1 (2005).
   Google Scholar
• Wax MB, Camras CB, Fiscella RG, Girkin C, Singh K, Weinreb RN. Emerging perspectives in glaucoma, optimizing 24-hour control of intraocular pressure. Am. J. Ophthalmol.133, S1–S10 (2002).
   Google Scholar
• Barkana Y, Anis S, Liebmann J, Tello C, Ritch R. Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma. Arch. Ophthalmol.124, 793–797 (2006).
   PubMed Web of Science ®Google Scholar